Detection of single amyloid β-protein aggregates in the cerebrospinal fluid of Alzheimer's patients by fluorescence correlation spectroscopy

1998 ◽  
Vol 4 (7) ◽  
pp. 832-834 ◽  
Author(s):  
M. Pitschke ◽  
R. Prior ◽  
M. Haupt ◽  
D. Riesner
Keyword(s):  
Cerebrospinal Fluid ◽  
Fluorescence Correlation Spectroscopy ◽  
Amyloid Β ◽  
Protein Aggregates ◽  
Correlation Spectroscopy ◽  
Amyloid Β Protein ◽  
Fluorescence Correlation ◽  
Β Protein

scholarly journals Temporal Alterations in Cerebrospinal Fluid Amyloid β-Protein and Apolipoprotein E After Subarachnoid Hemorrhage

Stroke ◽  
2003 ◽  
Vol 34 (12) ◽  
Author(s):  
Andrew Kay ◽  
Axel Petzold ◽  
Mary Kerr ◽  
Geoff Keir ◽  
Ed Thompson ◽  
...  
Keyword(s):  
Cerebrospinal Fluid ◽  
Subarachnoid Hemorrhage ◽  
Apolipoprotein E ◽  
Amyloid Β ◽  
Amyloid Β Protein ◽  
Β Protein

Cerebrospinal Fluid from Alzheimer's Disease Patients Promotes Amyloid β-Protein Oligomerization

2010 ◽  
Vol 21 (1) ◽  
pp. 81-86 ◽  
Author(s):  
Tokuhei Ikeda ◽  
Kenjiro Ono ◽  
David Elashoff ◽  
Margaret M. Condron ◽  
Moeko Noguchi-Shinohara ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cerebrospinal Fluid ◽  
Amyloid Β ◽  
Protein Oligomerization ◽  
Amyloid Β Protein ◽  
Β Protein

scholarly journals Amyloid β-peptide polymerization studied using fluorescence correlation spectroscopy

1999 ◽  
Vol 6 (1) ◽  
pp. 53-62 ◽  
Author(s):  
Lars O Tjernberg ◽  
Aladdin Pramanik ◽  
Sofie Björling ◽  
Per Thyberg ◽  
Johan Thyberg ◽  
...  
Keyword(s):  
Fluorescence Correlation Spectroscopy ◽  
Amyloid Β ◽  
Correlation Spectroscopy ◽  
Amyloid Β Peptide ◽  
Fluorescence Correlation

Inactivation of seeding activity of amyloid β‐protein aggregates in vitro

2021 ◽  
Author(s):  
Hiroto Nakano ◽  
Tsuyoshi Hamaguchi ◽  
Tokuhei Ikeda ◽  
Takahiro Watanabe‐Nakayama ◽  
Kenjiro Ono ◽  
...  
Keyword(s):  
Amyloid Β ◽  
Protein Aggregates ◽  
Amyloid Β Protein ◽  
Β Protein

Cerebrospinal Fluid Soluble Amyloid-β Protein Precursor as a Potential Novel Biomarkers of Alzheimer's Disease

2012 ◽  
Vol 28 (1) ◽  
pp. 119-125 ◽  
Author(s):  
Piotr Lewczuk ◽  
Julius Popp ◽  
Natalia Lelental ◽  
Heike Kölsch ◽  
Wolfgang Maier ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cerebrospinal Fluid ◽  
Amyloid Β ◽  
Amyloid Β Protein ◽  
Protein Precursor ◽  
Β Protein ◽  
Novel Biomarkers

Amyloid-β Protein Precursor Cleavage Products in Postmortem Ventricular Cerebrospinal Fluid of Alzheimer’s Disease Patients

2015 ◽  
Vol 47 (2) ◽  
pp. 365-372 ◽  
Author(s):  
Daniela Hartl ◽  
Wei Gu ◽  
Manuel Mayhaus ◽  
Sabrina Pichler ◽  
Jakob Schöpe ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cerebrospinal Fluid ◽  
Amyloid Β ◽  
Amyloid Β Protein ◽  
Protein Precursor ◽  
Β Protein

scholarly journals Amyloidogenic Nanoplaques in Cerebrospinal Fluid: Relationship to Amyloid Brain Uptake and Clinical Alzheimer’s Disease in a Memory Clinic Cohort

2020 ◽  
Vol 77 (2) ◽  
pp. 831-842 ◽  
Author(s):  
Mari Aksnes ◽  
Ebba Glersen Müller ◽  
Ann Tiiman ◽  
Trine Holt Edwin ◽  
Lars Terenius ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cerebrospinal Fluid ◽  
Apoe Genotype ◽  
Amyloid Β ◽  
Correlation Spectroscopy ◽  
Brain Uptake ◽  
Memory Clinic ◽  
Fluorescence Correlation ◽  
Pathological Event

Background: Aggregation of amyloid-β (Aβ) is an early pathological event in Alzheimer’s disease (AD). Consequently, measures of pathogenic aggregated Aβ are attractive biomarkers for AD. Here, we use a recently developed Thioflavin-T-Fluorescence Correlation Spectroscopy (ThT-FCS) assay to quantify structured ThT-responsive protein aggregates, so-called nanoplaques, in the cerebrospinal fluid (CSF). Objective: The overall aim of this work was to assess whether ThT-FCS determined CSF nanoplaque levels could predict amyloid brain uptake as determined by 18F-Flutemetamol PET analysis. Further, we assess whether nanoplaque levels could predict clinical AD. Methods: Nanoplaque levels in the CSF from 54 memory clinic patients were compared between sub-groups classified by 18F-Flutemetamol PET as amyloid-positive or amyloid-negative, and by clinical assessment as AD or non-AD. Results: Nanoplaque levels did not differ between amyloid groups and could not predict brain amyloid uptake. However, nanoplaque levels were significantly increased in patients with clinical AD, and were significant predictors for AD when adjusting for age, sex, cognitive function, and apolipoprotein E (APOE) genotype. Conclusion: The concentration of nanoplaques in the CSF differentiates patients with clinical AD from non-AD patients.

Sign in / Sign up

Export Citation Format

Share Document